On Thursday, Pfizer Inc. (NYSE:PFE) and Alliance Foundation Trials, LLC (AFT) announced results from the Phase 3 PATINA trial. The trial demonstrated that the addition of IBRANCE (palbociclib) to ...
NEW YORK/WASHINGTON (Reuters) - The blood thinner Eliquis from Bristol Myers Squibb, Pfizer's breast cancer drug Ibrance and AbbVie's leukemia treatment Imbruvica are likely to be among 10 big-selling ...
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Semaglutide, the popular drug sold by Novo Nordisk as ...
Matthew Herper covers medical innovation — both its promise and its perils. Pfizer said Thursday its drug Ibrance showed efficacy in a group of breast cancer patients who do not currently have access ...
MiBolsilloColombia on MSN
Major drug price cuts coming in 2027, with discounts of up to 85% on key treatments
Medicare’s second round of drug price negotiations will cut prices on 15 expensive treatments by up to 85% starting in 2027, delivering major savings for taxpayers and beneficiaries.
As the US Centers for Medicare and Medicaid Services (CMS) has released the new prices for 15 drugs that have been added to the Inflation Reduction Act (IRA) an expert questions how closely these ...
Pfizer’s core drugs (pneumococcal vaccine Prevnar 13, cancer drug Ibrance, immunology drug Xeljanz and cardiovascular drug Eliquis) posted solid growth, offsetting generic competition to erectile ...
Novartis (NYSE: NVS) announced on Monday that the U.S. Food and Drug Administration (FDA) approved Kisqali as a first-line treatment for hormone receptor positive, human epidermal growth factor ...
LONDON (Reuters) - U.S. drugmaker Pfizer said on Wednesday it had won approval from the European Union for its best-selling breast cancer drug Ibrance, making it the first medicine of its kind to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback